The class
CETP inhibition is identified as the optimal target for managing dyslipidemia in systemic lupus erythematosus (Int Immunopharmacol 2025)
Original title: Potential of CETP inhibition in treating dyslipidemia in systemic lupus erythematosus: Novel and comprehensive evidence from clinical studies and Mendelian randomization
Using clinical data from 511 patients with systemic lupus erythematosus (SLE) and 706 healthy controls alongside bidirectional Mendelian randomization across 179 plasma lipid metabolites and lipid-lowering drug targets, researchers assessed the causal link between dyslipidemia and SLE risk. SLE patients had significantly reduced HDL-C, APOA1 and APOA4 alongside elevated triglycerides, APOC3, APOD and APOF (all P less than 0.0001). Mendelian randomization identified three lipid metabolites as causal factors for SLE and found that genetically proxied CETP inhibition significantly reduced SLE risk via HDL-C modulation (odds ratio 0.72, P equals 3.38E-08), a relationship confirmed by ELISA showing elevated peripheral blood CETP and reduced APOA4 in SLE patients correlating with disease activity, while genetically proxied PCSK9 inhibition showed no relevance. The authors conclude dyslipidemia is a causal antecedent of SLE and identify CETP as the optimal pharmacological target for managing SLE-associated dyslipidemia.
Original abstract
Objective: Cardiovascular diseases from abnormal lipid metabolism significantly increase mortality in systemic lupus erythematosus (SLE). The causal link between dyslipidemia and SLE is unclear.
Methods: Lipid metabolism in patients with SLE was evaluated based on clinical data from 511 patients with SLE and 706 healthy individuals. Bidirectional Mendelian randomization (MR) was employed to assess causal links between 179 plasma lipid metabolites, lipid-lowering drug targets, and SLE risk. Genetic instruments from GWAS and eQTL data were used to evaluate CETP and APOA4 effects. Peripheral blood CETP and apolipoprotein levels in SLE patients were validated via ELISA.
Results: SLE patients exhibited reduced HDL-C (P < 0.0001), APOA1 (P < 0.0001), and APOA4 (P < 0.0001), alongside elevated triglycerides (TG, P < 0.0001), APOC3, APOD, and APOF. MR identified three lipid metabolites-PC(18:2_20:4), TG(56:6), and TG(58:7)-as causal factors for SLE (P < 2.79E-5). CETP inhibition significantly reduced SLE risk via HDL-C modulation (OR = 0.72, P = 3.38E-08) and influenced LDL-C, TG, and apolipoproteins. Clinical validation confirmed elevated CETP and reduced APOA4 in SLE, correlating with disease activity. APOA4 activation showed protective effects, while PCSK9 inhibition lacked relevance.
Conclusion: Bidirectional Mendelian randomization analyses confirmed dyslipidemia as a causal antecedent to SLE, with no evidence of reverse causation. A variety of MR analyses and clinical validation indicated that targeting HDL-C regulation offers significant advantages for managing dyslipidemia in patients with SLE, with CETP identified as the optimal pharmacological target.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.